Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Isofol Medical ABOSTO:ISOFOL 23 12-1 Month Momentum % is -2.31% as of Sep. 07, 2026. GuruFocus rates OSTO:ISOFOL with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,358 Biotechnology companies, Isofol Medical AB ranks better than 64.51% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-07), Isofol Medical AB's 12-1 Month Momentum % is -2.31%.
The industry rank for Isofol Medical AB's 12-1 Month Momentum % or its related term are showing as below:
OSTO:ISOFOL's 12-1 Month Momentum % is ranked better than 64.51% of 1358
companies
in the Biotechnology industry
Industry Median: -21.14
vs OSTO:ISOFOL: -2.31
Isofol Medical AB (OSTO:ISOFOL) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Isofol Medical AB 12-1 Month Momentum % Related Terms
OSTO:ISOFOL vs VRTX, REGN, MRNA: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Isofol Medical AB's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Isofol Medical AB 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Isofol Medical AB's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Isofol Medical AB's 12-1 Month Momentum % falls into.
Isofol Medical AB (OSTO:ISOFOL) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Isofol Medical AB (OSTO:ISOFOL) has a 12-1 Month Momentum % of -2.31% as of Sep. 07, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Isofol Medical AB and its competitors. According to the industry distribution chart, Isofol Medical AB ranks #482 out of 1358 companies in the Biotechnology industry, placing it in the top 35.5%.
Is Isofol Medical AB's 12-1 Month Momentum % too high?
Isofol Medical AB's current 12-1 Month Momentum % is -2.31%. Based on the distribution chart, Isofol Medical AB ranks #482 out of 1358 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Isofol Medical AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Isofol Medical AB's 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Isofol Medical AB ranks #482 out of 1358 companies for 12-1 Month Momentum %. This puts Isofol Medical AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Isofol Medical AB and its competitors. Isofol Medical AB's current 12-1 Month Momentum % is -2.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Isofol Medical AB stock overvalued right now?
Isofol Medical AB (OSTO:ISOFOL) has a current 12-1 Month Momentum % of -2.31%. The current 12-1 Month Momentum % is -2.31%. Isofol Medical AB's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Isofol Medical AB (OSTO:ISOFOL), the current 12-1 Month Momentum % is -2.31% as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
23GF Score
Get the complete analysis for OSTO:ISOFOL
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ISOFOL has been successfully added to your 
